Pyrimidine derivatives, preparation method therefor and application of pyrimidine derivatives
What is AI technical title?
AI technical title is built by PatSnap AI team. It summarizes the technical point description of the patent document.
A technology of pyrimidines and derivatives, applied in the field of drug synthesis
Active Publication Date: 2018-02-02
SHENYANG PHARMA UNIVERSITY
View PDF3 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Although a series of PAK inhibitors have been disclosed, there is still no PAK inhibitor drug on the market, and it is still necessary to develop compounds with novel structures and better efficacy
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0137] Preparation of 2,4-dihydroxy-6-chloroquinazoline (M1)
[0138]Mix 2-amino-5-chlorobenzoic acid (15.0g, 0.087mol) with urea (52.3g, 0.87mol), heat to melt and react at 200°C for 3 hours, stop heating, let cool, add 300ml of water, stir and heat to reflux for 1 After 1 hour, it was suction filtered while it was hot, and the solid was dried to obtain 13.77 g of a light yellow solid, with a yield of 80.5%.
[0139] ESI-MS(m / z): 197[M+H] + .
[0140] Preparation of 2,4,6-trichloroquinazoline (M2)
[0141] Add 2,4-dihydroxy-6-chloroquinazoline (M1) (16.0g, 0.081mol) into the reaction flask, add phosphorus oxychloride (47ml, 0.515mol), and add N,N-di Methylaniline (31ml, 0.243mol) was heated and refluxed for 3 hours, stopped heating, allowed to cool and poured into 500ml of ice water, a brownish black solid was precipitated, suction filtered, dried, and column chromatography (petrole...
Embodiment 1
[0183] Example 1: N 4 -(2-(1H-indol-3-yl)ethyl)-N 2 Preparation of -(1H-indazol-5-yl)quinazoline-2,4-diamine
[0184]
[0185] Step A-1 Preparation of N-(2-(1H-indol-3-yl)ethyl)-2-chloroquinazolin-4-amine (1)
[0186] Disperse 1.98g (0.01mol) of 2,4-dichloroquinazoline and 1.76g (0.0011mol) of tryptamine in 50ml of DMF, slowly add 0.32g (0.025mol) of DIEA into the solution under stirring in an ice bath, and drop it in After reacting for 2 hours at a reaction temperature of 0°C, pour it into 300ml of ice water to precipitate a light yellow solid, filter it with suction, and dry it to obtain 2.70 g of a light yellow solid with a yield of 83.4%. ESI-MS (m / z): 323 [M+ H] + .
[0187] Step A-2N 4 -(2-(1H-indol-3-yl)ethyl)-N 2 Preparation of -(1H-indazol-5-yl)quinazoline-2,4-diamine
[0188] Add 0.32 g (0.001 mol) of intermediate (1) and 0.27 g (0.002 mol) of 5-aminoindazole into the sealed tube, add 10 ml of absolute ethanol and 10 uL of hydrochloric acid, react at 120 de...
Embodiment 2
[0190] Example 2: N 4 -(2-(1H-indol-3-yl)ethyl)-N 2 -(1H-Indazol-5-yl)-6-methoxyquinazoline-2,4-diamine
[0191] ESI-MS(m / z): 450[M+H] + .
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention belongs to the field of drug synthesis and relates to novel pyrimidine derivatives, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, preparation methods of thenovel pyrimidine derivatives and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof and use of the novel pyrimidine derivatives and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof in preparation of therapeutic agents, particularly PAK inhibitors. The derivatives disclosed by the invention are represented by a general formula (I) or (II), wherein each substituent is as defined in claims.
Description
technical field [0001] The invention belongs to the field of drug synthesis, and relates to a class of novel pyrimidine derivatives, pharmaceutically acceptable salts, hydrates, solvates or prodrugs of the derivatives, their preparation methods and their use in the preparation of therapeutic agents, especially Use in the preparation of PAK inhibitors. Background technique [0002] Proteinkinase is currently the largest known protein superfamily. Since the discovery of proteinkinase activity in 1954, research in this field has developed rapidly. There are about 538 protein kinases that have been discovered, and their coding genes account for about About 2% of the human genome. As follows: [0003] [0004] Proteinkinase catalyzes the transfer of the terminal phosphate group of ATP to a specific amino acid of the substrate in vivo to phosphorylate the substrate. According to the type of amino acid residues phosphorylated in the substrate protein, they can be divided in...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.